Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 16/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112129 | 0.88 | P2RX4 (0.39) | OPRD1P2RX4KCNH2CYP2D6OPRM1 | |
| SCHEMBL5125316 | 0.88 | OPRD1 (0.45) | OPRD1P2RX4KCNH2OPRM1OPRK1 | |
| SCHEMBL3168207 | 0.86 | OPRD1 (0.49) | OPRD1P2RX4KCNH2CYP2D6OPRM1 | |
| SCHEMBL13395006 | 0.86 | OPRD1 (0.49) | OPRD1P2RX4KCNH2CYP2D6OPRM1 | |
| SCHEMBL13394994 | 0.86 | OPRD1 (0.49) | OPRD1P2RX4KCNH2CYP2D6OPRM1 | |
| SCHEMBL14000445 | 0.85 | PARP2 (0.41) | OPRD1KCNH2CYP2D6OPRM1OPRK1 | |
| SCHEMBL3182429 | 0.84 | OPRM1 (0.48) | OPRD1P2RX4OPRM1 | |
| SCHEMBL5112872 | 0.84 | KDM4E (0.44) | OPRD1P2RX4OPRM1OPRK1 | |
| SCHEMBL5112789 | 0.83 | OPRD1 (0.51) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5117821 | 0.82 | OPRD1 (0.40) | OPRD1P2RX4OPRM1OPRK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| EP-1846400-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006074388-A2 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148823-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885P2RX4 147/4885KCNH2 618/4885 |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885P2RX4 147/4885KCNH2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.